Hearn J Cho
Multiple Myeloma Research Foundation · Chief Medical Officer · Multiple Myeloma Research Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hearn J Cho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06171685 · MMRC Horizon One: RRMM (MMRC-099)Multiple Myeloma Research Consortium · active not recruiting · Relapse Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1/Ph2NCT04150965 · Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITMultiple Myeloma Research Consortium · terminated · Multiple Myeloma, Relapsed Refractory Multiple Myeloma · principal investigator
- Ph1/Ph2NCT03732703 · Myeloma-Developing Regimens Using Genomics (MyDRUG)Multiple Myeloma Research Consortium · completed · Relapsed Refractory Multiple Myeloma · principal investigator
- N/ANCT03657251 · MMRF CureCloud Research InitiativeMultiple Myeloma Research Foundation · terminated · Multiple Myeloma · principal investigator
- Ph1NCT01380145 · MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationLudwig Institute for Cancer Research · completed · Multiple Myeloma · study chair
- Ph2NCT00843310 · Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaNYU Langone Health · terminated · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Novel therapeutic strategies targeting conformational plasticity of type I MAGER21CA191898 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2015 to 2016 · $182,588 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:57 UTC. The ranking covers the 200 most relevant of 106 PubMed records, and a shared surname and initials can bring in a namesake. All 106 on PubMed
- 696 citationsRCR 15.3
- Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer.Cancer Discov · 2021203 citationsRCR 8.7
- 156 citationsRCR 19.7
- 152 citationsRCR 3.8
- 146 citationsRCR 4.7
- 106 citationsRCR 3.4
- 100 citationsRCR 6.3
- A prospective randomized study comparing arthroscopic single-bundle and double-bundle posterior cruciate ligament reconstructions preserving remnant fibers.Am J Sports Med · 201192 citationsRCR 5.0
- Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy.Gynecol Oncol · 200783 citationsRCR 2.7
- Trait sensitivity to social disconnection enhances pro-inflammatory responses to a randomized controlled trial of endotoxin.Psychoneuroendocrinology · 201564 citationsRCR 2.6